8-K: Evoke Pharma Reports Strong Q1 2024 Sales Growth Despite Headwinds, Reaffirms $14M Revenue Guidance

Evoke Pharma announced a 114% year-over-year increase in net product sales for Q1 2024, driven by a 70% growth in prescribers, despite facing challenges from a cyberattack and increased co-pay expenses.

Summary

• Evoke Pharma reported a 114% increase in net product sales, reaching approximately $1.7 million in the first quarter of 2024, compared to $0.8 million in the same period last year.
• The company experienced a 70% quarter-over-quarter growth in the number of prescribers for GIMOTI, their primary product.
• Despite a cyberattack on a major medical claims processor and increased co-pay expenses, Evoke saw a 10% increase in medication fills.
• The net loss for the quarter was approximately $1.6 million, or $0.17 per share, an improvement from a $2.2 million loss, or $0.67 per share, in Q1 2023.
• Evoke raised $8.8 million in gross proceeds through a public offering and warrant exercises, providing cash runway into the fourth quarter of 2024, with a potential additional $21.8 million if warrants are fully exercised.
• The company reaffirmed its net revenue guidance of approximately $14 million for 2024.
• Cash and cash equivalents were approximately $9.7 million as of March 31, 2024, which is expected to fund operations into the first quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong sales growth and improved financial metrics, but there are some concerns about the cyberattack, increased expenses, and reliance on a single product.

Positives

• The company achieved a significant 114% year-over-year increase in net product sales.
• There was a substantial 70% quarter-over-quarter growth in the number of prescribers.
• The company successfully raised $8.8 million in gross proceeds, strengthening its financial position.
• The net loss per share improved significantly compared to the same quarter last year.
• Evoke has a strong cash position of $9.7 million, expected to fund operations into Q1 2025.
• The company's partnership with ASPN Pharmacies is expected to enhance service delivery and patient reach.

Negatives

• The company experienced a cyberattack on a major medical claims processor, which disrupted new patient enrollments and refill adjudications.
• Increased co-pay expenses impacted net revenue due to lower payor reimbursements and higher patient deductibles.
• Selling, general, and administrative expenses increased to $3.1 million from $2.8 million in the same quarter last year.
• The company reported a net loss of approximately $1.6 million for the quarter.

Risks

• The company's 2024 revenue guidance is dependent on various factors, including market demand, reimbursements, and external factors like the global macroeconomic environment.
• There is a risk that warrant holders may not exercise their warrants, potentially limiting additional funding.
• Evoke is dependent on third parties for the manufacturing of GIMOTI.
• The company is entirely dependent on the success of GIMOTI.
• There are risks associated with inadequate efficacy or adverse side effects of GIMOTI, which could lead to recalls or product liability claims.
• The company faces risks related to maintaining intellectual property protection for GIMOTI.

Future Outlook

Evoke anticipates accelerated growth throughout the remainder of 2024 and reiterates its net revenue guidance of approximately $14 million for the year. The company believes its current cash and future sales will fund operations into the first quarter of 2025.

Management Comments

• The results achieved in the first quarter of 2024 reflect continued momentum with the adoption of GIMOTI.
• The real-world healthcare utilization data, including outcomes from over 500 patients, have consistently supported GIMOTI's efficacy for diabetic gastroparesis treatment compared to oral.
• We are confident that the issues from this quarter will fully resolve as the year progresses.
• Moving forward, we will amplify our promotional efforts for GIMOTI through the insights of our KOLs, real-world data, and conferences such as the upcoming Digestive Disease Week (DDW).

Industry Context

The announcement highlights the growing adoption of nasal metoclopramide (GIMOTI) for treating diabetic gastroparesis, a condition where oral medications may be less effective due to delayed gastric emptying. This aligns with the industry's focus on developing alternative drug delivery methods to improve patient outcomes.

Comparison to Industry Standards

• While specific competitor data isn't provided, the 114% year-over-year sales growth and 70% prescriber growth suggest strong market traction for GIMOTI compared to typical pharmaceutical product launches.
• The company's focus on real-world data and KOL engagement is a common strategy in the pharmaceutical industry to drive adoption of new treatments.
• The challenges faced by Evoke, such as the cyberattack and reimbursement issues, are not uncommon in the healthcare sector, highlighting the need for robust risk management strategies.
• The company's cash runway into Q1 2025 is a positive sign, but the dependence on GIMOTI's success is a risk factor that is common for companies with a single product.

Stakeholder Impact

• Shareholders will be positively impacted by the strong sales growth and improved financial performance.
• Patients will benefit from increased access to GIMOTI through the partnership with ASPN Pharmacies.
• Employees may experience increased job security due to the company's improved financial position.

Next Steps

• Evoke will continue to maximize GIMOTI awareness through KOLs and conferences.
• The company will present data on the clinical use of nasal metoclopramide at Digestive Disease Week (DDW).
• Evoke will continue to scale up GIMOTI distribution infrastructure with ASPN Pharmacies.

Key Dates

Keywords

GIMOTI, metoclopramide, gastroparesis, net product sales, pharmaceutical, revenue, prescribers, cyberattack, financial results, ASPN Pharmacies